To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program.

H.R. 5179 aims to change how Medicare calculates payments for prescription drugs and biological products administered in doctor's offices under Medicare Part B. The bill would require the government to increase reimbursement rates to ensure they are never lower than the actual market price physicians pay to acquire the drugs. By excluding certain "prompt pay" discounts from the official price calculation, the legislation seeks to ensure that healthcare providers are fully reimbursed for the cost of life-saving treatments, such as chemotherapy or vaccines, thereby protecting patient access to these medications in local clinical settings.